Stay updated with breaking news from Met High. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Reports Full-Year Diluted EPS of $2.72 on a GAAP Basis, a Decrease of 59.0 Percent; Adjusted Diluted EPS of $11.11, a Decrease of 19.3 Percent; These Results...
/PRNewswire/ -- AbbVie (NYSE: ABBV) announced today topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in...
AbbVie Inc (NYSE: ABBV) announced topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal growth factor receptor (EGFR) wild type,
Biopharmaceutical company AbbVie, Inc. (ABBV) announced Wednesday topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal growth factor receptor (EGFR) wild type, advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC).
Wila Matos KINGSTON, R.I. – May 5, 2021 – University of Rhode Island senior Wila Matos of Providence has participated in community service projects in Atlanta and Baltimore, studied Portuguese, sustainability and fisheries in Cape Verde, and mentored high school students at The Met High School. Now she is preparing to spend nine months in Brazil as the recipient of a Fulbright fellowship. “I’m super excited and honored to be a Fulbright finalist,” said Matos, speaking from Cape Verde, where she is continuing her studies of Portuguese and Cape Verdean Creole and learning about the ...